Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 3:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Retinal Detachment Clear all
Completed No phase listed Observational

A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events

NCT03479736
View directory record Official record
Conditions
Retinal Detachment, Achilles Tendon, Aneurysm, Dissecting
Interventions
Oral Fluoroquinolones (FQ), Other Antibiotics, Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
117,911 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Sep 7, 2026, 3:19 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Mac-off Retinal Detachment

NCT05730218
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment - Macula Off
Interventions
ONL1204 Ophthalmic Solution, Sham treatment
Drug
Lead sponsor
ONL Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
36
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Sep 7, 2026, 3:19 AM EDT
Completed Not applicable Interventional Results available

Use of Ocular Point of Care Ultrasound in Diagnosing Retinal Detachment in the Emergency Department

NCT03106025
View directory record Official record
Conditions
Retinal Detachment
Interventions
Ultrasound, Ophthalmology Assessment
Device · Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Sep 7, 2026, 3:19 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Dropless Pars Plana Vitrectomy Study

NCT05331664
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment
Interventions
Pars plana vitrectomy, Triamcinolone Acetonide 40mg/mL, Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin, Prednisolone 1%, Atropine 1%
Procedure · Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
40 Years and older
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 7, 2026, 3:19 AM EDT
Completed Phase 3 Interventional Results available

The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy

NCT04136366
View directory record Official record
Conditions
Proliferative Vitreoretinopathy
Interventions
ADX-2191 (intravitreal methotrexate 0.8%), Standard surgical care procedure
Drug · Other
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Sep 7, 2026, 3:19 AM EDT
Recruiting Not applicable Interventional

Retinal Detachment Prevention (Laser Prophylaxis) in Stickler Syndrome (SS)

NCT07146516
View directory record Official record
Conditions
Stickler Syndrome Type 1, Stickler Syndrome Type 2
Interventions
Prophylactic (non-invasive) Laser Retinopexy
Procedure
Lead sponsor
Helen Keller Eye Research Foundation
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
5
States / cities
Birmingham, Alabama • Royal Oak, Michigan • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 7, 2026, 3:19 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Quantification & Classification of Inflammatory Cells in Uveitis Using OCT

NCT07065747
View directory record Official record
Conditions
Anterior Uveitis (AU), Birdshot Chorioretinitis, Behcet Disease, Herpes Simplex Virus, Juvenile Idiopathic Arthritis (JIA), Spondyloarthritis (SA), Sarcoidosis, Posterior Vitreous Detachment
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
5 Years to 85 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Sep 7, 2026, 3:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

DISCOVER Study: Microscope-integrated Intraoperative OCT Study

NCT02423213
View directory record Official record
Conditions
Retinal Diseases, Fuchs Endothelial Dystrophy, Macular Hole, Epiretinal Membrane, Retinal Detachment
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
2,911 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 7, 2026, 3:19 AM EDT
Completed No phase listed Observational

Comparison of a Spectral OCT/SLO With the Stratus OCT for Imaging Various Retinal Pathologies

NCT00408720
View directory record Official record
Conditions
Macular Hole, RPE Detachment, Epiretinal Membrane, Posterior Vitreous Detachment
Interventions
Not listed
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
18 Years to 95 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2006 · Synced Sep 7, 2026, 3:19 AM EDT
Not listed Phase 2Phase 3 Interventional

A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR

NCT05660447
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Interventions
Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 7, 2026, 3:19 AM EDT
Completed No phase listed Observational

Ultrasound to Detect Evidence for Retinal Detachment in Retinopathy of Prematurity

NCT00279669
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Ultrasound examination
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Sep 7, 2026, 3:19 AM EDT
Terminated Not applicable Interventional

Vitreous Surgery With Intraocular Assistance

NCT02574624
View directory record Official record
Conditions
Traction Retinal Detachments, Rhegmatogenous Retinal Detachments, Dislocated Intraocular Lens
Interventions
Intraocular assistance
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Sep 7, 2026, 3:19 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment

NCT06033703
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Interventions
Netarsudil Ophthalmic
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Sep 7, 2026, 3:19 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab Against Recurrent Retinal Detachment

NCT02192970
View directory record Official record
Conditions
Retinal Detachment, Proliferative Vitreoretinopathy
Interventions
Bevacizumab
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 7, 2026, 3:19 AM EDT
Terminated Phase 1 Interventional

iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)

NCT01334255
View directory record Official record
Conditions
Pigment Epithelial Detachment
Interventions
iSONEP (sonepcizumab/LT1009)
Drug
Lead sponsor
Lpath, Inc.
Industry
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
5
States / cities
Winter Haven, Florida • West Mifflin, Pennsylvania • West Columbia, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Sep 7, 2026, 3:19 AM EDT
Completed Not applicable Interventional Results available

Avastin for PDR (Proliferative Diabetic Retinopathy)

NCT01270542
View directory record Official record
Conditions
Retinal Detachment, Diabetic Retinopathy
Interventions
Avastin (bevacizumab), Sham injection
Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Sep 7, 2026, 3:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

PIONEER: Intraoperative and Perioperative OCT Study

NCT02423161
View directory record Official record
Conditions
Retinal Detachment, Epiretinal Membrane, Macular Hole, Fuchs Endothelial Dystrophy
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 7, 2026, 3:19 AM EDT
Completed Phase 1 Interventional

Dexamethasone Implant for Retinal Detachment in Uveal Melanoma

NCT04082962
View directory record Official record
Conditions
Exudative Retinal Detachment and Uveal Melanoma
Interventions
Dexamethasone intravitreal implant
Drug
Lead sponsor
Ivana K. Kim
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 7, 2026, 3:19 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Intraoperative OCT Guidance of Intraocular Surgery II

NCT03713268
View directory record Official record
Conditions
Macular Holes, Epiretinal Membrane, Diabetic Retinopathy, Retinal Detachment, Retinal Disease, Preretinal Fibrosis, Cataract, Ocular Tumor, Strabismus, Healthy
Interventions
Microscope integrated optical coherence tomography
Device
Lead sponsor
Duke University
Other
Eligibility
4 Weeks and older
Enrollment
262 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 7, 2026, 3:19 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity

NCT00634972
View directory record Official record
Conditions
Retinopathy of Prematurity, Retinal Detachment, Blindness
Interventions
ACULAR, REFRESH TEARS, placebo
Drug
Lead sponsor
University of South Alabama
Other
Eligibility
10 Days to 15 Days
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 7, 2026, 3:19 AM EDT
Recruiting Phase 2 Interventional

Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial

NCT06541574
View directory record Official record
Conditions
Proliferative Vitreoretinopathy, Rhegmatogenous Retinal Detachment
Interventions
Methotrexate Injection, Methotrexate Infusion, Sham Injection
Drug
Lead sponsor
Cincinnati Eye Institute, Southwest Ohio
Other
Eligibility
18 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 7, 2026, 3:19 AM EDT
Not listed Phase 2 Interventional

Analysis of Aqueous and Vitreous Humor

NCT02067013
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy, Macular Degeneration, Macular Hole, Neovascular Glaucoma
Interventions
Ranibizumab, No Ranibizumab
Drug · Other
Lead sponsor
California Retina Consultants
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 7, 2026, 3:19 AM EDT
Not listed Phase 2 Interventional

Pneumatic Displacement of Subretinal Hemorrhage With Perfluorocarbon Gases

NCT00161525
View directory record Official record
Conditions
Subretinal Hemorrhage and Exudative Maculopathy
Interventions
Pneumatic displacement
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
20 Years to 95 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 3, 2011 · Synced Sep 7, 2026, 3:19 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR

NCT02681809
View directory record Official record
Conditions
Diabetic Retinopathy, Posterior Vitreous Detachment, Disease Progression
Interventions
ocriplasmin 0.0625mg, ocriplasmin 0.125mg, Sham injection
Drug
Lead sponsor
ThromboGenics
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
9
States / cities
Phoenix, Arizona • Campbell, California • Irvine, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2020 · Synced Sep 7, 2026, 3:19 AM EDT